Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Gains from Sales and Divestitures (2021 - 2024)

Opus Genetics (IRD) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $33614.0 as the latest value for Q3 2023.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $33614.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $33614.0, a N/A change, with the full-year FY2021 number at $40000.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $33614.0 for Q3 2023 at Opus Genetics, roughly flat from $33614.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $40000.0 in Q1 2021 to a low of $33614.0 in Q2 2023.